Project Details
Description
Project Summary
Leukemia inhibitory factor (LIF) is a multi-functional cytokine. Our previous studies reveal that LIF is a
direct target gene of tumor suppressor p53 and mediates the function of p53 in maternal reproduction, and
at the same time, LIF forms a negative feedback loop with p53 to inhibit p53 function in tumor suppression.
LIF has a complex role in tumorigenesis; LIF has been reported to suppress or promote tumorigenesis in
different types of cancers. Emerging evidence, including ours, has shown that LIF is frequently
overexpressed in colorectal cancer (CRC). Further, LIF overexpression is often associated with poor
prognosis in CRC patients. These observations strongly suggest a critical role of LIF in promoting colorectal
tumorigenesis. Currently, the precise role and mechanism of LIF in colorectal tumorigenesis are poorly
defined. Colorectal tumor-initiating stem-like cells (TICs) play a critical role in CRC initiation, progression
and resistance to therapy. Eliminating TICs has been actively tested as a therapeutic strategy for CRC.
Our recent study shows that LIF is present in the intestinal stem cells (ISC) niche and is essential to
maintain ISC number and functions. Oncogenic activation in ISCs plays a critical role in the initiation of
CRC. Our preliminary studies further suggest that LIF drives lipid metabolic reprogramming of colorectal
TICs as an important mechanism whereby LIF promotes colorectal TIC number and functions. These
findings prompt us to hypothesize that LIF is essential for colorectal TIC number and functions, which in
turn promotes colorectal tumorigenesis. We further hypothesize that targeting LIF and LIF-driven
metabolic reprogramming can suppress colorectal TICs and inhibit colorectal tumorigenesis. In this
proposed study, we will determine the role of LIF in colorectal tumorigenesis and colorectal TIC number
and functions by using different mouse models (Aim 1). We will determine whether increasing colorectal
TIC number and functions through LIF-driven lipid metabolic reprograming is a critical mechanism whereby
LIF promotes colorectal tumorigenesis. We will investigate whether LIF regulates the levels and activities
of critical transcription factors involved in lipid metabolism in colorectal TICs, including p53, to drive lipid
metabolic reprogramming (Aim 2A). We will further test whether the LIF-driven metabolic reprogramming
can be targeted for CRC therapy (Aim 2B). The goal of this study is to elucidate the role and mechanism
of LIF in CRC, and assess whether targeting LIF-driven lipid metabolic reprogramming is an effective
strategy to eliminate TICs and treat CRC with LIF overexpression. If accomplished successfully, this study
will establish the critical role of LIF in CRC, reveal its underlying mechanisms, and provide the rationale
and base for the development of new therapeutic targets and strategies for CRC with LIF overexpression.
Status | Active |
---|---|
Effective start/end date | 2/1/22 → 1/31/26 |
Funding
- National Cancer Institute: $368,879.00
- National Cancer Institute: $203,916.00
- National Cancer Institute: $372,497.00
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.